New Position Statement Aims to Guide the Use of AI Methods in Health Technology Assessment
Canada’s Drug Agency has published a new position statement on the use of artificial intelligence (AI) methods in health technology assessment (HTA).
The work of Canada’s Drug Agency is grounded in the independent assessment and evaluation of evidence, which is provided to health system leaders along with expert advice, enabling them to make informed decisions on drugs, health technologies, and health systems.
Evolving the Patient Group Input Process in Drug Reimbursement Reviews
Enhancing how we involve patient organizations and people with lived experience in our work is a key ambition at Canada’s Drug Agency. As part of our continuous improvement efforts, we are launching a new initiative that aims to evolve our approach to incorporating the patient voice in our drug reimbursement reviews.
Partnership remains a key guiding principle for Canada’s Drug Agency, and we continue our work to cultivate meaningful relationships with patient communities to strengthen the quality and significance of our work.